Precision BioSciences rises on US patent for gene editing therapy

Precision Biosciences

27/09/2023 13:05

** Precision BioSciences'  DTIL.O  shares rise 7.6% to 40
cents premarket
    ** Co says its application for the elimination of a type of
mutant mitochondrial DNA has received a U.S. patent allowance 
    ** Says once issued, the patent will have a standard
expiration date in April 2042
    ** DTIL's experimental therapy, PBGENE-PMM, eliminates
mutant mitochondrial DNA to allow repopulation of normal
mitchondrial DNA and re-establish normal function
    ** Up to last close, shares were down 68.3% YTD
    


 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))